STARGLO Dulled: Genentech’s Columvi Data Not Generalizable To US Patients, FDA Panel Says

 
• By Sue Sutter
  
Commissioner Makary and CBER Director Prasad stopped by the 20 May ODAC meeting. (Sue Sutter)

More from US Advisory Committees

More from Product Reviews